Publication
Textural features and SUV-based variables assessed by dual time point 18F-FDG PET/CT in locally advanced breast cancer
A.M. García-Vicente, D. Molina, J. Pérez-Beteta, M. Amo-Salas, A. Martínez-González, G. Bueno, M.J. Tello-Galán, A. Soriano-Castrejón
Annals of Nuclear Medicine 31(10) 726-735 (2017)
MOLAB authors
Amo Salas, Mariano. Martínez González, Alicia. Molina García, David. Pérez Beteta, Julián. García Vicente, Ana M.. 
Abstract
Aim To study the influence of dual time point 18F-FDG PET/CT in textural features and SUV-based variables and their relation among them.
Methods Fifty-six patients with locally advanced breast cancer (LABC) were prospectively included. All of them underwent a standard 18F-FDG PET/CT (PET-1) and a delayed acquisition (PET-2). After segmentation, SUV variables (SUVmax, SUVmean, and SUVpeak), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were obtained. Eighteen three-dimensional (3D) textural measures were computed including: run-length matrices (RLM) features, co-occurrence matrices (CM) features, and energies. Differences between all PET-derived variables obtained in PET-1 and PET-2 were studied.
Results Significant differences were found between the SUV-based parameters and MTV obtained in the dual time point PET/CT, with higher values of SUV-based variables and lower MTV in the PET-2 with respect to the PET-1. In relation with the textural parameters obtained in dual time point acquisition, significant differences were found for the short run emphasis, low gray-level run emphasis, short run high gray-level emphasis, run percentage, long run
emphasis, gray-level non-uniformity, homogeneity, and dissimilarity. Textural variables showed relations with MTV and TLG.
Conclusion Significant differences of textural features were found in dual time point 18F-FDG PET/CT. Thus, a dynamic behavior of metabolic characteristics should be expected, with higher heterogeneity in delayed PET acquisition compared with the standard PET. A greater heterogeneity was found in bigger tumors.